2018•World Journal of Clinical CasesOpen access

CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication

Tsung‐Jung Lin, Hsi‐Chang Lee, Chih‐Lin Lin, Chung-Kwe Wang, Kuan-Yang Chen, Deng‐Chyang Wu

Abstract

AIM: ) eradication by using rabeprazole-based hybrid therapy. METHODS: eradication therapy. The genotypes of CYP2C19 and IL-1β were analyzed to investigate the impact on treatment effect. RESULTS: . CONCLUSION: eradication using rabeprazole-based hybrid therapy.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 7 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Rabeprazole, CYP2C19, Helicobacter pylori, Medicine, Internal medicine, Gastroenterology, Genotype, Omeprazole